Classical complement pathway factor alterations in narcolepsy.

IF 3.8 4区医学 Q1 Medicine

Acta Neuropsychiatrica Pub Date : 2022-08-01 Epub Date: 2022-01-17 DOI:10.1017/neu.2021.42

Hande Yüceer, Duygu Gezen Ak, Gülçin Benbir Şenel, Erdinç Dursun, Vuslat Yılmaz, Derya Karadeniz, Erdem Tüzün, Cem İsmail Küçükali

{"title":"Classical complement pathway factor alterations in narcolepsy.","authors":"Hande Yüceer, Duygu Gezen Ak, Gülçin Benbir Şenel, Erdinç Dursun, Vuslat Yılmaz, Derya Karadeniz, Erdem Tüzün, Cem İsmail Küçükali","doi":"10.1017/neu.2021.42","DOIUrl":null,"url":null,"abstract":"Objective: Narcolepsy is a chronic sleep disorder long hypothesised to be an autoimmune disease. Complement-mediated immune mechanisms have not been investigated in detail in narcolepsy. Our aim was to establish the significance of classical pathway activation in narcolepsy.Methods: Sera of 42 narcolepsy patients and 26 healthy controls were screened with ELISA to determine the levels of C1q, C3a, C4d and complement component 4 binding protein (C4BP). A home-made ELISA method was developed to detect antibodies to C4BP-alpha (anti-C4BPA). The correlation between complement levels and clinical findings was examined.Results: C1q levels were significantly higher in narcolepsy patients while C4d and C4BP levels were significantly lower compared to healthy controls. C3a levels were comparable among patients and controls. Eleven narcolepsy patients showed serum anti-C4BPA levels. Total rapid eye movements (REM) time, sleep onset latency, REM sleep latency, sleep activity, percentage of wakefulness after sleep onset and Epworth sleepiness scale scores were correlated with levels of different complement factors.Conclusion: Complement-mediated immune mechanisms might partake in narcolepsy pathogenesis. The precise role of autoantibodies on complement level alterations needs to be investigated. Levels of complement factors and degradation products may potentially be utilised as biomarkers to predict the clinical severity of narcolepsy.","PeriodicalId":7066,"journal":{"name":"Acta Neuropsychiatrica","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropsychiatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/neu.2021.42","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: Narcolepsy is a chronic sleep disorder long hypothesised to be an autoimmune disease. Complement-mediated immune mechanisms have not been investigated in detail in narcolepsy. Our aim was to establish the significance of classical pathway activation in narcolepsy.

Methods: Sera of 42 narcolepsy patients and 26 healthy controls were screened with ELISA to determine the levels of C1q, C3a, C4d and complement component 4 binding protein (C4BP). A home-made ELISA method was developed to detect antibodies to C4BP-alpha (anti-C4BPA). The correlation between complement levels and clinical findings was examined.

Results: C1q levels were significantly higher in narcolepsy patients while C4d and C4BP levels were significantly lower compared to healthy controls. C3a levels were comparable among patients and controls. Eleven narcolepsy patients showed serum anti-C4BPA levels. Total rapid eye movements (REM) time, sleep onset latency, REM sleep latency, sleep activity, percentage of wakefulness after sleep onset and Epworth sleepiness scale scores were correlated with levels of different complement factors.

Conclusion: Complement-mediated immune mechanisms might partake in narcolepsy pathogenesis. The precise role of autoantibodies on complement level alterations needs to be investigated. Levels of complement factors and degradation products may potentially be utilised as biomarkers to predict the clinical severity of narcolepsy.

查看原文本刊更多论文

发作性睡病的典型补体通路因子改变。

目的:嗜睡症是一种慢性睡眠障碍，长期以来被认为是一种自身免疫性疾病。补体介导的免疫机制在发作性睡症中尚未得到详细的研究。我们的目的是确定经典通路激活在发作性睡病中的意义。方法:采用ELISA法筛选42例发作性睡患者和26例健康对照者血清，检测C1q、C3a、C4d及补体组分4结合蛋白(C4BP)水平。建立了一种检测c4bp - α抗体(抗c4bpa)的自制ELISA方法。研究了补体水平与临床表现的相关性。结果:发作性睡病患者C1q水平显著高于健康对照组，C4d和C4BP水平显著低于健康对照组。C3a水平在患者和对照组之间具有可比性。11例发作性睡病患者血清抗c4bpa水平升高。总快速眼动(REM)时间、睡眠开始潜伏期、快速眼动睡眠潜伏期、睡眠活动性、睡眠开始后清醒百分比和Epworth嗜睡量表得分与补体因子水平相关。结论:补体介导的免疫机制可能参与发作性睡病的发病机制。自身抗体在补体水平改变中的确切作用有待研究。补体因子和降解产物的水平可能被用作预测发作性睡病临床严重程度的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Neuropsychiatrica 医学-精神病学

CiteScore

8.50

自引率

5.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal''s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health.